NASDAQ · ORIC
Oric Pharmaceuticals, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ORIC: Nov 12, 2026
Oric Pharmaceuticals, Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.41. The reported EPS for the same quarter last year was $-0.33.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.41 | $-0.40 | $-0.43 | 5 |
| Dec 2026 | $-0.42 | $-0.41 | $-0.46 | 5 |
| Mar 2027 | $-0.44 | $-0.39 | $-0.48 | 5 |
| Jun 2027 | $-0.47 | $-0.41 | $-0.59 | 5 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
MarketBeat · RTTNews · Fintel · BNK Invest- MarketBeat · Oct 23, 1:04 PM EDTOric Pharmaceuticals’ Enozertinib Shows 88% Response Rate in EGFR Lung Cancer StudyOric Pharmaceuticals (NASDAQ:ORIC) reported updated Phase 1b data for enozertinib in previously untreated patients with advanced non-small cell lung cancer (NSCLC) carrying atypical EGFR mutations, highlighting systemic and intracranial responses in a cohort with a high prevalenc
- RTTNews · Oct 23, 11:00 AM EDTORIC Pharmaceuticals Plans Phase 3 Trial For Enozertinib After Promising Lung Cancer Data(RTTNews) – ORIC Pharmaceuticals (ORIC) presented clinical data for enozertinib, an investigational EGFR inhibitor, in patients with previously untreated non-small cell lung cancer (NSCLC) carrying atypical EGFR mutations at the ESMO Congress 2026.
- Fintel · Oct 23, 9:12 AM EDTORIC Pharmaceuticals, Inc. Announces Phase 1b Enozertinib Data and Plans for Phase 3 Redwood-1 Trial in 1H 2027ORIC Pharmaceuticals, Inc. presented an enozertinib (ORIC-114) program update on October 23, 2026 at ESMO Congress 2026. The update covered data from the Phase 1b trial in patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor recepto
- Fintel · Sep 23, 11:10 AM EDTBTIG Initiates Coverage of ORIC Pharmaceuticals at BuyFintel reports that on September 23, 2026, BTIG initiated coverage of ORIC Pharmaceuticals (NASDAQGS:ORIC) (DB:4TZ) with a Buy recommendation.ORIC Pharmaceuticals, Inc., based in the United States, operates within the biotechnology sector, primarily focusing on the development of
- RTTNews · Aug 4, 2:16 AM EDTORIC Q2 Loss Widens As Phase 3 Trial For Prostate Cancer Progresses; Stock Down(RTTNews) – ORIC Pharmaceuticals, Inc. (ORIC), a clinical-stage oncology company, reported a wider net loss for the second quarter ended June 30, 2026, and provided updates on its clinical pipeline.
- BNK Invest · Jun 2, 12:01 PM EDTTuesday's ETF Movers: XSD, XBIIn trading on Tuesday, the SPDR S&P Semiconductor ETF is outperforming other ETFs, up about 5.7% on the day. Components of that ETF showing particular strength include shares of Marvell Technology, up about 27.3% and shares of Penguin Solutions, up about 20.4% on the day.
- RTTNews · May 5, 6:55 AM EDTORIC Reports Q1 Results; Highlights Progressing Trials For Cancer Therapies(RTTNews) – ORIC Pharmaceuticals Inc. (ORIC), a clinical-stage oncology company, on Monday released the first quarter financial results and provided operational updates on the development of drugs Rinzimetostat and Enozertinib.
- Barchart · Apr 2, 2:53 PM EDTStocks Settle Higher on Hopes for Conclusion to Iran WarThe S&P 500 Index ($SPX ) (SPY ) on Wednesday closed up +0.72%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.18%. June E-mini S&P futures (ESM26 ) rose +0.74%, and June E-mini Nasdaq futures…
- Barchart · Apr 1, 7:38 PM EDTStocks Climb on War-End OptimismThe S&P 500 Index ($SPX ) (SPY ) today is up +0.97%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.86%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.45%. June E-mini S&P futures (ESM26 ) are up +0.96%, and June E-mini Nasdaq futures…
- Barchart · Apr 1, 7:18 PM EDTStocks Rally on Optimism that the War in Iran is Near a ConclusionThe S&P 500 Index ($SPX ) (SPY ) today is up +0.52%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.43%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.68%. June E-mini S&P futures (ESM26 ) are up +0.57%, and June E-mini Nasdaq futures…
- RTTNews · Apr 1, 11:39 AM EDTOric Pharma Unveils Rinzimetostat Phase Ib Data And Outlines Phase III Study In Prostate Cancer(RTTNews) – Oric Pharmaceuticals (ORIC), a clinical-stage biopharmaceutical company, reported new dose-optimisation results for its Rinzimetostat or ORIC-944 from the Phase Ib Study, and outlined plans to begin its first phase III registrational study in metastatic castration-res
- Zacks · Mar 9, 9:55 AM EDTAfter Golden Cross, Oric Pharmaceuticals, Inc. (ORIC)'s Technical Outlook is BrightWhen a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Oric Pharmaceuticals, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.